Data from the following clinical trials are discussed:

+ breast cancer identifies recurrent pathway alterations associated with anti-HER2 resistance and new therapeutic vulnerabilities

GS1-05: Datopotamab deruxtecan (Dato-DXd) in advanced/metastatic HER2- breast cancer: results from the phase 1 TROPION-PanTumor01 study

GS04-09: Quality-of-life results from OlympiA: a phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after neoadjuvant chemotherapy in patients with germline 

Videos

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer. 

SABCS 2021: Novel Approaches to Breast Cancer Management 

PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis in 

+ breast cancer: Results from TBCRC049, a phase 2 nonrandomized study

PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated 

+ metastatic breast cancer with brain metastases (HER2CLIMB)

P1-18-26: Intracranial efficacy of tucatinib, palbociclib, and letrozole combination in patients with HR+/

P1-21-03: Efficacy of tyrosine kinase inhibitors (TKIs) in the treatment of patients with 

+ breast cancer with or without brain metastases: a systematic review and meta-analysis

OT1-13-01: HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with 

+ locally advanced or metastatic breast cancer with and without brain metastases

Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.

SABCS 2021: Brain Metastases Updates in Breast Cancer 

GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs trastuzumab emtansine (T-DM1) in patients with 

–positive metastatic breast cancer: subgroup analyses from the randomized phase 3 study DESTINYBreast03

GS3-02: Updated overall survival (OS) results from the phase 3 PHOEBE trial pyrotinib vs lapatinib in combination with capecitabine in patients with 

GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor (HR)–positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: latest updates from the SUMMIT trial

P2-13-10: First-in-human HER2-targeted bispecific antibody KN026 for the treatment of patients with 

+ metastatic breast cancer: results from a phase I study

P2-13-07: Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy for 

+ breast cancer: results from a phase 1 study

PD8-07: Evaluation of tucatinib + paclitaxel + pertuzumab + trastuzumab followed by AC (doxorubicin hydrochloride, cyclophosphamide) in high-risk HER2+ stage II/III breast cancer: results from the I-SPY2 trial

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting. 

Heather McArthur, MD, MPH

Articles

SABCS 2021: Novel Approaches to Breast Cancer Management

SABCS 2021: Brain Metastases Updates in Breast Cancer

SABCS 2021: Updates in Metastatic Breast Cancer